Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Financing Activities (2021 - 2025)

Lyra Therapeutics has reported Cash from Financing Activities over the past 5 years, most recently at -$368000.0 for Q3 2025.

  • Quarterly results put Cash from Financing Activities at -$368000.0 for Q3 2025, down 1500.0% from a year ago — trailing twelve months through Dec 2025 was -$392000.0 (down 104.6% YoY), and the annual figure for FY2025 was $4.3 million, down 49.91%.
  • Cash from Financing Activities for Q3 2025 was -$368000.0 at Lyra Therapeutics, down from -$1000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for LYRA hit a ceiling of $96.5 million in Q2 2022 and a floor of -$418000.0 in Q3 2023.
  • Median Cash from Financing Activities over the past 5 years was $1500.0 (2023), compared with a mean of $10.7 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 216000.0% in 2024 and later crashed 1500.0% in 2025.
  • Lyra Therapeutics' Cash from Financing Activities stood at -$4000.0 in 2021, then crashed by 5800.0% to -$236000.0 in 2022, then soared by 8116.95% to $18.9 million in 2023, then plummeted by 100.01% to -$1000.0 in 2024, then crashed by 36700.0% to -$368000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were -$368000.0 (Q3 2025), -$1000.0 (Q4 2024), and -$23000.0 (Q3 2024) per Business Quant data.